The trial, which included 2,260 adolescents, also showed that the vaccine was well tolerated by the group. The companies plan to submit the data to the U.S. Food and Drug Administration and the European Medicines Agency for a requested amendment to the emergency use authorization of BNT162b2; the companies also will request an expansion to the European Union conditional marketing authorization for the vaccine as soon as possible.

Additionally, Pfizer and BioNTech have initiated a study on the safety and efficacy of the vaccine in children ages 6 months to 11. Children ages 5 to 11 were the first to be given the vaccine.

Pfizer starts evaluation of SARS-CoV-2 oral antiviral
Pfizer is advancing its clinical research of PF-07321332, a new investigational oral antiviral therapy against SARS-CoV-2, to evaluate the safety and...

Pfizer-BioNTech study supports 97% effectiveness of COVID-19 vaccine
Real-world evidence released by the Israel Ministry of Health demonstrates dramatically lower incidence rates of COVID-19 disease in individuals fully...

Pfizer, BioNTech study 3rd booster of vaccine to protect against variants
Pfizer and BioNTech have started to evaluate the safety and immunogenicity of a third dose of their COVID-19 vaccine BNT162b2 as a booster on immunity...

Pfizer, BioNTech vaccine neutralizes SARS-CoV-2 variants in vitro
Pfizer and BioNTech has released results from in vitro neutralization studies of blood sera from individuals vaccinated with its COVID-19 vaccine, providing...

Covax to purchase 40M doses of Pfizer, BioNTech COVID-19 vaccine
The Covax global vaccine initiative has reached a deal with Pfizer and BioNTech for 40 million doses of the Pfizer-BioNTech COVID-19 vaccine.